<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02026921</url>
  </required_header>
  <id_info>
    <org_study_id>NSGO-OC-0303</org_study_id>
    <nct_id>NCT02026921</nct_id>
  </id_info>
  <brief_title>A Phase II Study of Docetaxel and Carboplatin in Late Relapse of Ovarian Cancer</brief_title>
  <official_title>A Phase II Study of Docetaxel and Carboplatin as Second Line Chemotherapy in First Relapse of Platinum Sensitive Epithelial Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nordic Society for Gynaecologic Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nordic Society for Gynaecologic Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase II single arm study of carboplatin and docetaxel in treatment of first sensitive
      relapse of epithelial ovarian, peritoneal or tubal cancer.

      Hypothesis: Treatment with this combination in second line is safe and with a low frequency
      of neurologic side effect.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluation of toxicity and response of treatment with carboplatin and docetaxel to patients
      with epithelial cancer of ovary, fallopian tube or peritoneum with their first relapse
      occurring at least 6 months after end of first line treatment- Evaluation of toxicity
      according to Clinical Toxicity Criteria version 2.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">March 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>Up to 30 days after last chemotherapy course</time_frame>
    <description>Safety will be established by grading the observed toxicities using the NCI Common Toxicity Criteria (CTC Version 2.0). All toxicities observed within 30 dayes of last chemocourse will be included.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>Up to 30 dayes after last chemotherapy course</time_frame>
    <description>Response rate according to Resist 1.0 Response rate is the proportion of patients that achieve CR or PR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Up to 3 year</time_frame>
    <description>Time from start of treatment to the earlier date of assessment of progression or death by any cause.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Ovarian Epithelial Cancer Recurrent</condition>
  <arm_group>
    <arm_group_label>Carboplatin and docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous infusion every 3 weeks Carboplatin plus docetaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin, AUC5, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: 6 or until progression or unacceptable toxicity develops</description>
    <arm_group_label>Carboplatin and docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: 6 or until progression or unacceptable toxicity develops.</description>
    <arm_group_label>Carboplatin and docetaxel</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Epithelial carcinoma of ovarian, peritoneal or fallopian tube origin.

          -  Female

          -  age above 18 years

          -  WHO performance status 0-2

          -  Life expectancy &gt; 3 months

          -  Previous treatment with one platinum and taxane containing regimen.

          -  Platinum and taxane sensitive relapse

          -  At least one evaluable/measurable lesion.

          -  Adequate hematologic, renal and liver function

          -  Consent form signed and dated before inclusion

        Exclusion Criteria:

          -  Prior treatment with more than one line of chemotherapy

          -  Concurrent severe and/or uncontrolled co-morbid medical condition.

          -  History of previous or concurrent malignancy within the previous 5 years • History of
             prior serious allergic reactions such as anaphylactic shock

          -  Pregnant or lactating women (or potentially fertile women not using adequate
             contraception)

          -  Peripheral neuropathy &gt; Grade 2

          -  History of allergy to drugs containing the excipient TWEEN 80®.

          -  Concomitant administration of any other experimental drug under investigation or
             concurrent treatment with any other anti-cancer therapy

          -  Clinical evidence of brain metastases
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gunnar B Kristensen, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>NSGO-CTU</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herlev University Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norwegian Radium Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0310</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Norway</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2013</study_first_submitted>
  <study_first_submitted_qc>December 31, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 3, 2014</study_first_posted>
  <last_update_submitted>December 31, 2013</last_update_submitted>
  <last_update_submitted_qc>December 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase II study,</keyword>
  <keyword>Recurrent platinum-sensitive ovarian cancer</keyword>
  <keyword>docetaxel</keyword>
  <keyword>Carboplatin</keyword>
  <keyword>Toxicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

